Kingdon Capital Management L.L.C. Has $3.15 Million Stock Position in Jasper Therapeutics, Inc. $JSPR

Kingdon Capital Management L.L.C. increased its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 93.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,324,845 shares of the company’s stock after buying an additional 640,138 shares during the quarter. Kingdon Capital Management L.L.C. owned 0.08% of Jasper Therapeutics worth $3,153,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Jasper Therapeutics by 65.4% in the third quarter. Vanguard Group Inc. now owns 1,032,842 shares of the company’s stock worth $2,458,000 after acquiring an additional 408,245 shares during the last quarter. Propel Bio Management LLC acquired a new position in Jasper Therapeutics during the 3rd quarter worth approximately $2,449,000. Simplify Asset Management Inc. bought a new position in Jasper Therapeutics in the 3rd quarter valued at approximately $1,450,000. Boothbay Fund Management LLC acquired a new stake in Jasper Therapeutics in the third quarter valued at approximately $1,053,000. Finally, Goldman Sachs Group Inc. boosted its position in Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after buying an additional 23,453 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on JSPR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Thursday, January 22nd. Rodman & Renshaw began coverage on shares of Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.88.

Jasper Therapeutics Trading Down 3.9%

NASDAQ JSPR opened at $1.22 on Monday. The firm has a market capitalization of $34.14 million, a PE ratio of -0.21 and a beta of 3.08. The business’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $1.89. Jasper Therapeutics, Inc. has a 12 month low of $1.11 and a 12 month high of $7.19.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.